Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors by McHugh, Deaglan J., Feldman, Darren R.

Get full text

Testicular cancer in 2023: Current status and recent progress by McHugh, Deaglan J., Gleeson, Jack P., Feldman, Darren R.

Get full text

Androgen‐deprivation therapy, dementia, and cognitive dysfunction in men with prostate cancer: How much smoke and how much fire? by McHugh, Deaglan J., Root, James C., Nelson, Christian J., Morris, Michael J.

Get full text

Corrigendum to “Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial” [Eur. Urol. 86(2) (2024) 90–94] by Fitzgerald, Kelly N., Lee, Chung-Han, Voss, Martin H., Carlo, Maria I., Knezevic, Andrea, Peralta, Laura, Chen, Yingbei, Lefkowitz, Robert A., Shah, Neil J., Owens, Colette N., McHugh, Deaglan J., Aggen, David H., Laccetti, Andrew L., Kotecha, Ritesh R., Feldman, Darren R., Motzer, Robert J.

Get full text

Ototoxicity associated with high‐dose carboplatin for patients with previously treated germ cell tumors by Funt, Samuel A., Knezevic, Andrea, Wilson, Kaamilah, Bromberg, Maria, Budnick, Amy, O’Connor, Kerri L., McHugh, Deaglan J., Larsen, Erik, Bajorin, Dean F., Motzer, Robert J., Tonorezos, Emily S., Patil, Sujata, Feldman, Darren R.

Get full text

Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial by Fitzgerald, Kelly N., Lee, Chung-Han, Voss, Martin H., Carlo, Maria I., Knezevic, Andrea, Peralta, Laura, Chen, Yingbei, Lefkowitz, Robert A., Shah, Neil J., Owens, Colette N., McHugh, Deaglan J., Aggen, David H., Laccetti, Andrew L., Kotecha, Ritesh R., Feldman, Darren R., Motzer, Robert J.

Get full text

Four Cycles of Etoposide plus Cisplatin for Patients with Good‐Risk Advanced Germ Cell Tumors by Funt, Samuel A., McHugh, Deaglan J., Tsai, Stephanie, Knezevic, Andrea, O'Donnell, Devon, Patil, Sujata, Silber, Deborah, Bromberg, Maria, Carousso, Maryann, Reuter, Victor E., Carver, Brett S., Sheinfeld, Joel, Motzer, Robert J., Bajorin, Dean F., Bosl, George J., Feldman, Darren R.

Get full text

A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer by McHugh, Deaglan J., Chudow, Jay, DeNunzio, Mia, Slovin, Susan F., Danila, Daniel C., Morris, Michael J., Scher, Howard I., Rathkopf, Dana E.

Get full text

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" Eur. Urol. 86(2) (2024) 90-94 by Fitzgerald, Kelly N, Lee, Chung-Han, Voss, Martin H, Carlo, Maria I, Knezevic, Andrea, Peralta, Laura, Chen, Yingbei, Lefkowitz, Robert A, Shah, Neil J, Owens, Colette N, McHugh, Deaglan J, Aggen, David H, Laccetti, Andrew L, Kotecha, Ritesh R, Feldman, Darren R, Motzer, Robert J

Get full text

A Phase I Trial of IGF-IR Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-Resistant Prostate Cancer by McHugh, Deaglan J., Chudow, Jay, DeNunzio, Mia, Slovin, Susan F., Danila, Daniel C., Morris, Michael J., Scher, Howard I., Rathkopf, Dana E.

Get full text

A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer by McHugh, Deaglan, Tagawa, Scott, Moryl, Natalie, Milowsky, Matthew, Heller, Glenn, Osborne, Joseph, Rathkopf, Dana, Basch, Ethan, Pandit-Taskar, Neeta, Morris, Michael J.

Get full text

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer by McHugh, Deaglan, Eisenberger, Mario, Heath, Elisabeth I., Bruce, Justine, Danila, Daniel C., Rathkopf, Dana E., Feldman, Jarett, Slovin, Susan F., Anand, Banmeet, Chu, Rong, Lackey, Jacqueline, Reyno, Leonard, Antonarakis, Emmanuel S., Morris, Michael J.

Get full text